Immunohistochemical Stain Facilitates cHL Diagnosis
By LabMedica International staff writers Posted on 11 Mar 2019 |
Image: Immunohistochemical stain for CD137 performed on paraffin-embedded tissue sections (cytoplasmic and membranous) using monoclonal BBK-2 clone (original magnification ×400) (Photo courtesy of Peter N. Carbone, MD and Qian-Yun Zhang, MD, PhD).
Remarkable efforts are underway to exploit classic Hodgkin lymphoma's (cHL) complex interplay of molecular alterations, loss of B-cell programming, and dependency of tumor microenvironment.
Tumor necrosis factor receptor superfamily member 9 or CD137 has been shown to induce proliferation and enhance the survival and function of T cells, natural killer cells, and dendritic cells. Conceptually, agonistic anti-CD137 is categorized as a co-stimulatory immunotherapy with the potential to manipulate the tumor microenvironment and accentuate antitumor response.
Pathologists at the Naval Medical Center Portsmouth (Portsmouth, VA, USA) and The University of New Mexico School of Medicine (Albuquerque, NM, USA) constructed tissue microarrays from formalin-fixed, paraffin-embedded tissue including 42 cases of cHL, 33 cases of nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), 16 cases of anaplastic large cell lymphoma, and seven cases of T-cell/histiocyte–rich large B-cell lymphoma. They validated anti-CD137 monoclonal BBK-2 clone, using protease retrieval and a dilution of 1:100.Tissue microarrays were then stained with CD137 as well as CD15, CD20, and CD30 and reviewed by two pathologists.
The scientists assigned positive staining if 20% or more of the malignant cells were positive regardless of strength of staining. Of the cHL cases, 76% were positive for CD137, 85% were positive for CD15, 100% were positive for CD30, and 13% were positive for CD20. Interestingly, CD137 was positive in all cHL cases where CD15 was negative. Conversely, CD15 was positive in 88% of cHL cases that were negative for CD137. Furthermore, CD137 was positive in 6% of NLPHL cases, 38% of anaplastic large cell lymphoma cases, and in none of the T-cell/histiocyte–rich large B-cell lymphoma cases.
The authors concluded that, although CD137 is not specific for cHL, it has utility in the immunohistochemistry (IHC) evaluation for cHL, in particular when the morphologic distinction with NLPHL is challenging. Additionally, it is easy to interpret, with minimal nonspecific background staining. Lastly, CD137 expression has been identified in several solid and hematopoietic neoplasms, and determination of this expression via IHC may prove to be a valuable biomarker of response to CD137 immunotherapy. The study was published in the March 2019 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
Naval Medical Center Portsmouth
University of New Mexico School of Medicine
Tumor necrosis factor receptor superfamily member 9 or CD137 has been shown to induce proliferation and enhance the survival and function of T cells, natural killer cells, and dendritic cells. Conceptually, agonistic anti-CD137 is categorized as a co-stimulatory immunotherapy with the potential to manipulate the tumor microenvironment and accentuate antitumor response.
Pathologists at the Naval Medical Center Portsmouth (Portsmouth, VA, USA) and The University of New Mexico School of Medicine (Albuquerque, NM, USA) constructed tissue microarrays from formalin-fixed, paraffin-embedded tissue including 42 cases of cHL, 33 cases of nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), 16 cases of anaplastic large cell lymphoma, and seven cases of T-cell/histiocyte–rich large B-cell lymphoma. They validated anti-CD137 monoclonal BBK-2 clone, using protease retrieval and a dilution of 1:100.Tissue microarrays were then stained with CD137 as well as CD15, CD20, and CD30 and reviewed by two pathologists.
The scientists assigned positive staining if 20% or more of the malignant cells were positive regardless of strength of staining. Of the cHL cases, 76% were positive for CD137, 85% were positive for CD15, 100% were positive for CD30, and 13% were positive for CD20. Interestingly, CD137 was positive in all cHL cases where CD15 was negative. Conversely, CD15 was positive in 88% of cHL cases that were negative for CD137. Furthermore, CD137 was positive in 6% of NLPHL cases, 38% of anaplastic large cell lymphoma cases, and in none of the T-cell/histiocyte–rich large B-cell lymphoma cases.
The authors concluded that, although CD137 is not specific for cHL, it has utility in the immunohistochemistry (IHC) evaluation for cHL, in particular when the morphologic distinction with NLPHL is challenging. Additionally, it is easy to interpret, with minimal nonspecific background staining. Lastly, CD137 expression has been identified in several solid and hematopoietic neoplasms, and determination of this expression via IHC may prove to be a valuable biomarker of response to CD137 immunotherapy. The study was published in the March 2019 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
Naval Medical Center Portsmouth
University of New Mexico School of Medicine
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes